Ildong Pharmaceutical, a leading player in the pharmaceutical industry, has released its 3Q 2023 Interim Report on Business Performance. The report reveals a 3.0% decline in current quarter sales compared to the previous quarter, resulting in a cumulative sales decrease of 7.4% year-on-year.
Operating income, on the other hand, exhibits a positive trend with a 10.7% improvement from the preceding period. However, net income from continuing operations before income tax experienced a substantial decline, marking a significant shift in the company’s financial landscape.
It is important to note that these results are presented based on K-IFRS and are subject to potential adjustments following an external auditor review.
